Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05586061 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer

Study acronym: RCTS
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study completion date: Dec 31, 2024 to Dec 31, 2025v3
  2. Start date changed from estimate of Nov 1, 2022 to Feb 10, 2023
    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Nov 1, 2024 to Dec 29, 2024
    • Site contacts updated at 6 of 7 sites
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, single arm, multicenter phase II study aimed at evaluating the efficacy and safety of Disitamab Vedotin in Combination With Tirelizumab and S-1 as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Trial Details
NCT Number NCT05586061
Lead Sponsor Qilu Hospital of Shandong University
Conditions
(from sponsor)		 HER2-positive Gastric Cancer
Enrollment 55 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov